Yumanity Therapeutics, Inc. (YMTX) News & Overview - Discounting Cash Flows
YMTX
Yumanity Therapeutics, Inc.
YMTX (NASDAQ)

YMTX's Business Model

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Sector & Industry Healthcare / Biotechnology
Website https://www.yumanity.com
CEO (Chief Executive Officer)
Number of Employees
IPO date February 11, 2016

YMTX Latest News

Contact
CountryUS
Address40 Guest Street
CityBoston
StateMA
Phone617 409 5300
Zip Code02135
Other Identifiers
CIK0001445283
ISINUS98872L1026
CUSIP98872L102
Open1.63
Previous Close1.74
Volume697.5 Thou.
Average Volume132.4 Thou.
Day’s Range1.4 – 1.89
52 Week Range0.95-3.37
MA (50)1.767714
MA (200)1.585122
Market Cap15.72 Mil.
Shares Out.8.32 Mil.
Earnings Date
Beta
Last Dividend
EPS
PE

Industry Competitors for YMTX

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us